

3's Company: COX-2 Inhibitors, Medicinal Marijuana, and Opioid Prescribing

Alexandra L. McPherson, PharmD, MPH

#### **Disclosure**

Alexandra L. McPherson, PharmD, MPH Palliative Care Clinical Pharmacy Specialist MedStar Washington Hospital Center, Washington, DC



Painweek.

# **Learning Objectives**

- 1) Evaluate treatment safety and efficacy of COX-2 inhibitors for the management of chronic pain
- 2) Interpret current literature regarding the benefits and burdens of medicinal vs recreational cannabis
- 3) Appropriately apply the CDC guidelines for prescribing opioids for chronic pain

Tha	E۵	ata

- Prevalence of chronic pain in US adult population ~11.2%
- There is an opioid epidemic
  - 1991-2014: 165,000 people died from opioid overdose in the US
- There is focus on the need for nonopioid medications to treat pain
- NSAIDs may be reasonable consideration as alternatives
- Marijuana is trendy and becoming more accepted and available for medicinal purposes
- Opioids are good analgesics for some people
- Opioid medications are a major target of the media and the government in attempt to control the epidemic

# I'm going to attempt to iron this out for you!



Painweek.



Cox-2 Inhibitors: Good, Bad, or Ugly?

N	9	Δ	ı	D	c

- In 2012, more than 98 million NSAID prescriptions were filled
- More than 23 million Americans use NSAIDs daily
- Utilization is likely to increase with aging of America
- Shift away from opioids will likely increase NSAID use

PainWeek http://www.nsaidalliance.com/wp-content/uploads/2014/10/NSAID-Alliance-NSAID-Fact-Sheet.pdf


#### **NSAIDs**

- ■5%-7% of hospital admissions are related to adverse effects of drugs  $\rightarrow$  NSAIDs are responsible for 11%-12% of these
- Significant dose and duration-dependent gastrointestinal, renal, and cardiovascular adverse events with selective and nonselective NSAIDs
- NSAID use is a major cause of GI ulcers
- NSAID-induced GI complications result in > 100,000 hospitalizations and > 16,500 deaths annually

Painweek http://www.nsaidalliance.com/wp-content/uploads/2014/10/NSAID-Alliance-NSAID-Fact-Sheet.pdf

#### **Mechanism of Action**

- NSAIDs inhibit COX or prostaglandin synthase (PGHS)
- Impairing the ultimate transformation of arachidonic acid to prostaglandins, prostacyclin, and thromboxanes



PainWeek. UpToDate, 2017, "Overview of selective COX-2 inhibitors"

COX-1  • Expressed in most tissues, variably • Housekeeping' enzyme — Regulates normal cellular processes — Gastro cytoprotection — Vascular homeostasis — Platelet agregation — Kidney function — Kidney function — Video function	■ Expressed in most tissues, variably ■ 'Housekeeping' enzyme ■ Regulates normal cellular processes Gastric cytoprotection ■ 'Vascular homeostasis ■ Patietet aggregation ■ Kidney function ■ Stimulated by hormones or growth factors  ■ UpToDate, 2017, 'Overview of selective COX-2 inhibitors'  ■ The nonsecretory cytoprotective effects of PG include: ■ Stimulation of clygoprotein (mucin) secretion by epithelial cells ■ Stimulation of phospholipid secretion by epithelial cells ■ Stimulation of phospholipid secretion by epithelial cells ■ Enhancement of mucosal blood flow and oxygen delivery to epithelial cell via local vasodilation ■ Increased epithelial cell migration towards the luminal surface (restitution) ■ Enhanced epithelial cell proliferation  ■ COX-2 ■ Expressed constitutively in the brain, kidney, bone, and female reproductive system ■ Expressed at other sites during states of inflammation ■ Expressed at other sites during states of inflammati		
Expressed in most tissues, variably     *Housekeeping* enzyme     - Regulates normal cellular processes     - Gastric cytoprotection     - Vascular homeostasis     - Platelet aggregation     - Kidney function  *Stimulated by hormones or growth factors  UpToDate, 2017, *Overview of selective COX-2 inhibitors*  *Normal Company of the company of t	Expressed in most tissues, variably	COX Enzymes	
Expressed in most tissues, variably     *Housekeeping* enzyme     - Regulates normal cellular processes     - Gastric cytoprotection     - Vascular homeostasis     - Platelet aggregation     - Kidney function  *Stimulated by hormones or growth factors  UpTobate, 2017. *Overview of selective COX-2 inhibitors*  *The nonsecretory cytoprotective effects of PG include:     - Stimulation of clygoprotein (mucin) secretion by epithelial cells     - Stimulation of phospholipid secretion by epithelial cells     - Stimulation of phospholipid secretion by epithelial cells     - Enhancement of mucosal blood flow and oxygen delivery to epithelial cell migration towards the luminal surface (restitution)     - Enhanced epithelial cell proliferation  **Pixersed at other sites during states of inflammation  **Expressed at other sites during states of inflammation   **Expressed at other sites during states of inflammation   **Expressed at other sites during states of inflammation   **Expressed at other sites during states of inflammation   **Expressed at other sites during states of inflammation   **Expressed at other sites during states of inflammation    **Expressed at other sites during states of inflammation    **Expressed at other sites during states of inflammation    **Expressed at other sites during states of inflammation    **Expressed at other sites during states of inflammation     **Expressed at other sites during states of inflammation     **Expressed at other sites during states of inflammation        **Expressed at other sites during states of inflammatio	■ Expressed in most tissues, variably ■ 'Housekeeping' enzyme — Regulates normal cellular processes — Gastric cytoprotection — Vascular homeostasis — Platelet aggregation — Kidney function ■ Stimulated by hormones or growth factors  ■ UpToDate, 2017, 'Overview of selective COX-2 inhibitors'  ■ The nonsecretory cytoprotective effects of PG include: — Stimulation of clygoprotein (mucin) secretion by epithelial cells — Stimulation of phospholipid secretion by epithelial cells — Stimulation of phospholipid secretion by epithelial cells — Stimulation of phospholipid secretion by epithelial cells — Enhancement of mucosal blood flow and oxygen delivery to epithelial cell migration towards the luminal surface (restitution) — Enhanced epithelial cell proliferation  ■ Expressed constitutively in the brain, kidney, ona of lemale reproductive system  ■ Expressed at other sites during states of inflammation  ■ Expressed at other sites during states of inflammation  ■ Expressed at other sites during states of inflammation  ■ Expressed at other sites during states of inflammation  ■ Expressed at other sites during states of inflammation  ■ Expressed at other sites during states of inflammation  ■ Expressed and female reproductive system  ■ Expresse	COX-1	COX-2
Regulates normal cellular processes - Gastric cytoprotection - Vascular homeostasis - Platelet aggregation - Kidney function  *Stimulated by hormones or growth factors  *UpToDate, 2017, "Overview of selective COX-2 inhibitors"  *The nonsecretory cytoprotective effects of PG include: - Stimulation of clygoprotein (mucin) secretion by epithelial cells - Stimulation of bicarbonate secretion by epithelial cells - Stimulation of phospholipid secretion by epithelial cells - Stimulation of phospholipid secretion by epithelial cells - Stimulation of phospholipid secretion by epithelial cells - Enhancement of mucosal blood flow and oxygen delivery to epithelial cells via local vasodilation - Increased epithelial cell migration towards the luminal surface (restitution) - Enhanced epithelial cell proliferation  Primarily due to inhibition of COX-I	Regulates normal cellular processes  Gastric cytoprotection  Vascular homeostasis Platelet aggregation - Kidney function  *Stimulated by hormones or growth factors  *UpToDate, 2017, "Overview of selective COX-2 inhibitors"  *The nonsecretory cytoprotective effects of PG include: - Stimulation of clygoprotein (mucin) secretion by epithelial cells - Stimulation of bicarbonate secretion by epithelial cells - Stimulation of phospholipid secretion by epithelial cells - Stimulation of phospholipid secretion by epithelial cells - Stimulation of phospholipid secretion by epithelial cells - Enhancement of mucosal blood flow and oxygen delivery to epithelial cell wia local vasodilation - Increased epithelial cell proliferation  Primarily due to inhibition of COX-1		■Expressed constitutively in the brain,
- Gastric cytoprotection - Vascular homeostasis - Platelet aggregation - Kidney function  - Stimulated by hormones or growth factors  - The nonsecretory cytoprotective effects of PG include: - Stimulation of clygoprotein (mucin) secretion by epithelial cells - Stimulation of bicarbonate secretion by epithelial cells - Stimulation of phospholipid secretion by epithelial cells - Stimulation of phospholipid secretion by epithelial cells - Stimulation of phospholipid secretion by epithelial cells - Enhancement of mucosal blood flow and oxygen delivery to epithelial cells wia local vasodilation - Increased epithelial cell migration towards the luminal surface (restitution) - Enhanced epithelial cell proliferation	- Gastric cytoprotection - Vascular homeostasis - Platelet aggregation - Kidney function  - Stimulated by hormones or growth factors  - The nonsecretory cytoprotective effects of PG include: - Stimulation of clygoprotein (mucin) secretion by epithelial cells - Stimulation of phospholipid secretion by epithelial cells - Enhancement of mucosal blood flow and oxygen delivery to epithelial cell wia local vasodilation - Increased epithelial cell proliferation  - Enhanced epithelial cell proliferation  - Primarily due to inhibition of COX-1		
- Vascular homeostasis - Platelet aggregation - Kidney function  • Stimulated by hormones or growth factors  - Platelet aggregation - Kidney function  • Stimulated by hormones or growth factors  - Platelet aggregation - The nonsecretory cytoprotective effects of PG include: - Stimulation of clygoprotein (mucin) secretion by epithelial cells - Stimulation of bicarbonate secretion by epithelial cells - Stimulation of phospholipid secretion by epithelial cells - Stimulation of phospholipid secretion by epithelial cells - Enhancement of mucosal blood flow and oxygen delivery to epithelial cells via local vasodilation - Increased epithelial cell migration towards the luminal surface (restitution) - Enhanced epithelial cell proliferation  - Primarily due to inhibition of COX-I	- Vascular homeostasis - Platelet aggregation - Kidney function  Stimulated by hormones or growth factors  - Platelet aggregation - Stimulated by hormones or growth factors  - Platelet aggregation - Stimulation of clygoprotective effects of PG include: - Stimulation of clygoprotein (mucin) secretion by epithelial cells - Stimulation of bicarbonate secretion by epithelial cells - Stimulation of phospholipid secretion by epithelial cells - Stimulation of phospholipid secretion by epithelial cells - Enhancement of mucosal blood flow and oxygen delivery to epithelial cells via local vasodilation - Increased epithelial cell migration towards the luminal surface (restitution) - Enhanced epithelial cell proliferation  Primarily due to inhibition of COX-1		
*Stimulated by hormones or growth factors  NSAIDS and Gastrointestinal Toxicity  The nonsecretory cytoprotective effects of PG include:  Stimulation of clygoprotein (mucin) secretion by epithelial cells  Stimulation of bicarbonate secretion by epithelial cells  Stimulation of phospholipid secretion by epithelial cells  Enhancement of mucosal blood flow and oxygen delivery to epithelial cells via local vasodilation  Increased epithelial cell migration towards the luminal surface (restitution)  Enhanced epithelial cell proliferation  Primarily due to inhibition of COX-I	*Stimulated by hormones or growth factors  NSAIDS and Gastrointestinal Toxicity  The nonsecretory cytoprotective effects of PG include:  Stimulation of clygoprotein (mucin) secretion by epithelial cells  Stimulation of bicarbonate secretion by epithelial cells  Stimulation of phospholipid secretion by epithelial cells  Stimulation of mucosal blood flow and oxygen delivery to epithelial cells via local vasodilation  Increased epithelial cell migration towards the luminal surface (restitution)  Enhanced epithelial cell proliferation  Primarily due to inhibition of COX-1	- Vascular homeostasis	
Stimulated by hormones or growth factors  NSAIDS and Gastrointestinal Toxicity  The nonsecretory cytoprotective effects of PG include:  Stimulation of clygoprotein (mucin) secretion by epithelial cells  Stimulation of phospholipid secretion by epithelial cells  Stimulation of phospholipid secretion by epithelial cells  Stimulation of phospholipid secretion by epithelial cells  Increased epithelial cell migration towards the luminal surface (restitution)  Enhanced epithelial cell proliferation  Primarily due to inhibition of COX-I	Stimulated by hormones or growth factors  NSAIDS and Gastrointestinal Toxicity  The nonsecretory cytoprotective effects of PG include:  Stimulation of clygoprotein (mucin) secretion by epithelial cells  Stimulation of phospholipid secretion by epithelial cells  Stimulation of phospholipid secretion by epithelial cells  Enhancement of mucosal blood flow and oxygen delivery to epithelial cells via local vasodilation  Increased epithelial cell migration towards the luminal surface (restitution)  Enhanced epithelial cell proliferation  Primarily due to inhibition of COX-1		
NSAIDS and Gastrointestinal Toxicity  The nonsecretory cytoprotective effects of PG include:  Stimulation of clygoprotein (mucin) secretion by epithelial cells  Stimulation of phospholipid secretion by epithelial cells  Stimulation of phospholipid secretion by epithelial cells  Enhancement of mucosal blood flow and oxygen delivery to epithelial cells via local vasodilation  Increased epithelial cell migration towards the luminal surface (restitution)  Enhanced epithelial cell proliferation  Primarily due to inhibition of COX-I	NSAIDS and Gastrointestinal Toxicity  The nonsecretory cytoprotective effects of PG include:  Stimulation of clygoprotein (mucin) secretion by epithelial cells  Stimulation of phospholipid secretion by epithelial cells  Stimulation of phospholipid secretion by epithelial cells  Enhancement of mucosal blood flow and oxygen delivery to epithelial cells via local vasodilation  Increased epithelial cell migration towards the luminal surface (restitution)  Enhanced epithelial cell proliferation  Primarily due to inhibition of COX-I		
NSAIDS and Gastrointestinal Toxicity  The nonsecretory cytoprotective effects of PG include:  Stimulation of clygoprotein (mucin) secretion by epithelial cells  Stimulation of bicarbonate secretion by epithelial cells  Stimulation of phospholipid secretion by epithelial cells  Enhancement of mucosal blood flow and oxygen delivery to epithelial cells via local vasodilation  Increased epithelial cell migration towards the luminal surface (restitution)  Enhanced epithelial cell proliferation  Primarily due to inhibition of COX-I	NSAIDS and Gastrointestinal Toxicity  The nonsecretory cytoprotective effects of PG include:  Stimulation of clygoprotein (mucin) secretion by epithelial cells  Stimulation of bicarbonate secretion by epithelial cells  Stimulation of phospholipid secretion by epithelial cells  Enhancement of mucosal blood flow and oxygen delivery to epithelial cells via local vasodilation  Increased epithelial cell migration towards the luminal surface (restitution)  Enhanced epithelial cell proliferation  Primarily due to inhibition of COX-I		
NSAIDS and Gastrointestinal Toxicity  The nonsecretory cytoprotective effects of PG include:  Stimulation of clygoprotein (mucin) secretion by epithelial cells  Stimulation of bicarbonate secretion by epithelial cells  Stimulation of phospholipid secretion by epithelial cells  Enhancement of mucosal blood flow and oxygen delivery to epithelial cells via local vasodilation  Increased epithelial cell migration towards the luminal surface (restitution)  Enhanced epithelial cell proliferation  Primarily due to inhibition of COX-I	NSAIDS and Gastrointestinal Toxicity  The nonsecretory cytoprotective effects of PG include:  Stimulation of clygoprotein (mucin) secretion by epithelial cells  Stimulation of bicarbonate secretion by epithelial cells  Stimulation of phospholipid secretion by epithelial cells  Enhancement of mucosal blood flow and oxygen delivery to epithelial cells via local vasodilation  Increased epithelial cell migration towards the luminal surface (restitution)  Enhanced epithelial cell proliferation  Primarily due to inhibition of COX-I		
The nonsecretory cytoprotective effects of PG include:  Stimulation of clygoprotein (mucin) secretion by epithelial cells  Stimulation of bicarbonate secretion by epithelial cells  Stimulation of phospholipid secretion by epithelial cells  Enhancement of mucosal blood flow and oxygen delivery to epithelial cells via local vasodilation  Increased epithelial cell migration towards the luminal surface (restitution)  Enhanced epithelial cell proliferation  Primarily due to inhibition of COX-I	The nonsecretory cytoprotective effects of PG include:  Stimulation of clygoprotein (mucin) secretion by epithelial cells  Stimulation of bicarbonate secretion by epithelial cells  Stimulation of phospholipid secretion by epithelial cells  Enhancement of mucosal blood flow and oxygen delivery to epithelial cells via local vasodilation  Increased epithelial cell migration towards the luminal surface (restitution)  Enhanced epithelial cell proliferation  Primarily due to inhibition of COX-1	UpToDate, 2017, "Overview of sele	active COX-2 inhibitors"
The nonsecretory cytoprotective effects of PG include:  Stimulation of clygoprotein (mucin) secretion by epithelial cells  Stimulation of bicarbonate secretion by epithelial cells  Stimulation of phospholipid secretion by epithelial cells  Enhancement of mucosal blood flow and oxygen delivery to epithelial cells via local vasodilation  Increased epithelial cell migration towards the luminal surface (restitution)  Enhanced epithelial cell proliferation  Primarily due to inhibition of COX-I	The nonsecretory cytoprotective effects of PG include:  Stimulation of clygoprotein (mucin) secretion by epithelial cells  Stimulation of bicarbonate secretion by epithelial cells  Stimulation of phospholipid secretion by epithelial cells  Enhancement of mucosal blood flow and oxygen delivery to epithelial cells via local vasodilation  Increased epithelial cell migration towards the luminal surface (restitution)  Enhanced epithelial cell proliferation  Primarily due to inhibition of COX-1		
The nonsecretory cytoprotective effects of PG include:  -Stimulation of clygoprotein (mucin) secretion by epithelial cells -Stimulation of bicarbonate secretion by epithelial cells -Stimulation of phospholipid secretion by epithelial cells -Enhancement of mucosal blood flow and oxygen delivery to epithelial cells via local vasodilation -Increased epithelial cell migration towards the luminal surface (restitution) -Enhanced epithelial cell proliferation  Primarily due to inhibition of COX-I	The nonsecretory cytoprotective effects of PG include:  Stimulation of clygoprotein (mucin) secretion by epithelial cells  Stimulation of bicarbonate secretion by epithelial cells  Stimulation of phospholipid secretion by epithelial cells  Enhancement of mucosal blood flow and oxygen delivery to epithelial cells via local vasodilation  Increased epithelial cell migration towards the luminal surface (restitution)  Enhanced epithelial cell proliferation  Primarily due to inhibition of COX-1		
The nonsecretory cytoprotective effects of PG include:  Stimulation of clygoprotein (mucin) secretion by epithelial cells  Stimulation of bicarbonate secretion by epithelial cells  Stimulation of phospholipid secretion by epithelial cells  Enhancement of mucosal blood flow and oxygen delivery to epithelial cells via local vasodilation  Increased epithelial cell migration towards the luminal surface (restitution)  Enhanced epithelial cell proliferation  Primarily due to inhibition of COX-I	The nonsecretory cytoprotective effects of PG include:  Stimulation of clygoprotein (mucin) secretion by epithelial cells  Stimulation of bicarbonate secretion by epithelial cells  Stimulation of phospholipid secretion by epithelial cells  Enhancement of mucosal blood flow and oxygen delivery to epithelial cells via local vasodilation  Increased epithelial cell migration towards the luminal surface (restitution)  Enhanced epithelial cell proliferation  Primarily due to inhibition of COX-1		
The nonsecretory cytoprotective effects of PG include:  -Stimulation of clygoprotein (mucin) secretion by epithelial cells  -Stimulation of bicarbonate secretion by epithelial cells  -Stimulation of phospholipid secretion by epithelial cells  -Enhancement of mucosal blood flow and oxygen delivery to epithelial cells via local vasodilation  -Increased epithelial cell migration towards the luminal surface (restitution)  -Enhanced epithelial cell proliferation	The nonsecretory cytoprotective effects of PG include:  Stimulation of clygoprotein (mucin) secretion by epithelial cells  Stimulation of bicarbonate secretion by epithelial cells  Stimulation of phospholipid secretion by epithelial cells  Enhancement of mucosal blood flow and oxygen delivery to epithelial cells via local vasodilation  Increased epithelial cell migration towards the luminal surface (restitution)  Enhanced epithelial cell proliferation  Primarily due to inhibition of COX-1		
The nonsecretory cytoprotective effects of PG include:  Stimulation of clygoprotein (mucin) secretion by epithelial cells  Stimulation of bicarbonate secretion by epithelial cells  Stimulation of phospholipid secretion by epithelial cells  Enhancement of mucosal blood flow and oxygen delivery to epithelial cells via local vasodilation  Increased epithelial cell migration towards the luminal surface (restitution)  Enhanced epithelial cell proliferation  Primarily due to inhibition of COX-I	The nonsecretory cytoprotective effects of PG include:  Stimulation of clygoprotein (mucin) secretion by epithelial cells  Stimulation of bicarbonate secretion by epithelial cells  Stimulation of phospholipid secretion by epithelial cells  Enhancement of mucosal blood flow and oxygen delivery to epithelial cells via local vasodilation  Increased epithelial cell migration towards the luminal surface (restitution)  Enhanced epithelial cell proliferation  Primarily due to inhibition of COX-1		
The nonsecretory cytoprotective effects of PG include:  Stimulation of clygoprotein (mucin) secretion by epithelial cells  Stimulation of bicarbonate secretion by epithelial cells  Stimulation of phospholipid secretion by epithelial cells  Enhancement of mucosal blood flow and oxygen delivery to epithelial cells via local vasodilation  Increased epithelial cell migration towards the luminal surface (restitution)  Enhanced epithelial cell proliferation  Primarily due to inhibition of COX-I	The nonsecretory cytoprotective effects of PG include:  Stimulation of clygoprotein (mucin) secretion by epithelial cells  Stimulation of bicarbonate secretion by epithelial cells  Stimulation of phospholipid secretion by epithelial cells  Enhancement of mucosal blood flow and oxygen delivery to epithelial cells via local vasodilation  Increased epithelial cell migration towards the luminal surface (restitution)  Enhanced epithelial cell proliferation  Primarily due to inhibition of COX-1		
The nonsecretory cytoprotective effects of PG include:  Stimulation of clygoprotein (mucin) secretion by epithelial cells  Stimulation of bicarbonate secretion by epithelial cells  Stimulation of phospholipid secretion by epithelial cells  Enhancement of mucosal blood flow and oxygen delivery to epithelial cells via local vasodilation  Increased epithelial cell migration towards the luminal surface (restitution)  Enhanced epithelial cell proliferation  Primarily due to inhibition of COX-I	The nonsecretory cytoprotective effects of PG include:  Stimulation of clygoprotein (mucin) secretion by epithelial cells  Stimulation of bicarbonate secretion by epithelial cells  Stimulation of phospholipid secretion by epithelial cells  Enhancement of mucosal blood flow and oxygen delivery to epithelial cells via local vasodilation  Increased epithelial cell migration towards the luminal surface (restitution)  Enhanced epithelial cell proliferation  Primarily due to inhibition of COX-1		
The nonsecretory cytoprotective effects of PG include:  Stimulation of clygoprotein (mucin) secretion by epithelial cells  Stimulation of bicarbonate secretion by epithelial cells  Stimulation of phospholipid secretion by epithelial cells  Enhancement of mucosal blood flow and oxygen delivery to epithelial cells via local vasodilation  Increased epithelial cell migration towards the luminal surface (restitution)  Enhanced epithelial cell proliferation  Primarily due to inhibition of COX-I	The nonsecretory cytoprotective effects of PG include:  Stimulation of clygoprotein (mucin) secretion by epithelial cells  Stimulation of bicarbonate secretion by epithelial cells  Stimulation of phospholipid secretion by epithelial cells  Enhancement of mucosal blood flow and oxygen delivery to epithelial cells via local vasodilation  Increased epithelial cell migration towards the luminal surface (restitution)  Enhanced epithelial cell proliferation  Primarily due to inhibition of COX-1		
The nonsecretory cytoprotective effects of PG include:  Stimulation of clygoprotein (mucin) secretion by epithelial cells  Stimulation of bicarbonate secretion by epithelial cells  Stimulation of phospholipid secretion by epithelial cells  Enhancement of mucosal blood flow and oxygen delivery to epithelial cells via local vasodilation  Increased epithelial cell migration towards the luminal surface (restitution)  Enhanced epithelial cell proliferation  Primarily due to inhibition of COX-I	The nonsecretory cytoprotective effects of PG include:  Stimulation of clygoprotein (mucin) secretion by epithelial cells  Stimulation of bicarbonate secretion by epithelial cells  Stimulation of phospholipid secretion by epithelial cells  Enhancement of mucosal blood flow and oxygen delivery to epithelial cells via local vasodilation  Increased epithelial cell migration towards the luminal surface (restitution)  Enhanced epithelial cell proliferation  Primarily due to inhibition of COX-1		
The nonsecretory cytoprotective effects of PG include:  -Stimulation of clygoprotein (mucin) secretion by epithelial cells  -Stimulation of bicarbonate secretion by epithelial cells  -Stimulation of phospholipid secretion by epithelial cells  -Enhancement of mucosal blood flow and oxygen delivery to epithelial cells via local vasodilation  -Increased epithelial cell migration towards the luminal surface (restitution)  -Enhanced epithelial cell proliferation	The nonsecretory cytoprotective effects of PG include:  Stimulation of clygoprotein (mucin) secretion by epithelial cells  Stimulation of bicarbonate secretion by epithelial cells  Stimulation of phospholipid secretion by epithelial cells  Enhancement of mucosal blood flow and oxygen delivery to epithelial cells via local vasodilation  Increased epithelial cell migration towards the luminal surface (restitution)  Enhanced epithelial cell proliferation  Primarily due to inhibition of COX-1		
The nonsecretory cytoprotective effects of PG include:  Stimulation of clygoprotein (mucin) secretion by epithelial cells  Stimulation of bicarbonate secretion by epithelial cells  Stimulation of phospholipid secretion by epithelial cells  Enhancement of mucosal blood flow and oxygen delivery to epithelial cells via local vasodilation  Increased epithelial cell migration towards the luminal surface (restitution)  Enhanced epithelial cell proliferation  Primarily due to inhibition of COX-I	The nonsecretory cytoprotective effects of PG include:  Stimulation of clygoprotein (mucin) secretion by epithelial cells  Stimulation of bicarbonate secretion by epithelial cells  Stimulation of phospholipid secretion by epithelial cells  Enhancement of mucosal blood flow and oxygen delivery to epithelial cells via local vasodilation  Increased epithelial cell migration towards the luminal surface (restitution)  Enhanced epithelial cell proliferation  Primarily due to inhibition of COX-1		
The nonsecretory cytoprotective effects of PG include:  Stimulation of clygoprotein (mucin) secretion by epithelial cells  Stimulation of bicarbonate secretion by epithelial cells  Stimulation of phospholipid secretion by epithelial cells  Enhancement of mucosal blood flow and oxygen delivery to epithelial cells via local vasodilation  Increased epithelial cell migration towards the luminal surface (restitution)  Enhanced epithelial cell proliferation  Primarily due to inhibition of COX-I	The nonsecretory cytoprotective effects of PG include:  Stimulation of clygoprotein (mucin) secretion by epithelial cells  Stimulation of bicarbonate secretion by epithelial cells  Stimulation of phospholipid secretion by epithelial cells  Enhancement of mucosal blood flow and oxygen delivery to epithelial cells via local vasodilation  Increased epithelial cell migration towards the luminal surface (restitution)  Enhanced epithelial cell proliferation  Primarily due to inhibition of COX-1		
-Stimulation of clygoprotein (mucin) secretion by epithelial cells -Stimulation of bicarbonate secretion by epithelial cells -Stimulation of phospholipid secretion by epithelial cells -Enhancement of mucosal blood flow and oxygen delivery to epithelial cells via local vasodilation -Increased epithelial cell migration towards the luminal surface (restitution) -Enhanced epithelial cell proliferation  Primarily due to inhibition of COX-I	-Stimulation of clygoprotein (mucin) secretion by epithelial cells -Stimulation of bicarbonate secretion by epithelial cells -Stimulation of phospholipid secretion by epithelial cells -Enhancement of mucosal blood flow and oxygen delivery to epithelial cells via local vasodilation -Increased epithelial cell migration towards the luminal surface (restitution) -Enhanced epithelial cell proliferation  Primarily due to inhibition of COX-I	NSAIDS and Gastro	intestinal Toxicity
-Stimulation of clygoprotein (mucin) secretion by epithelial cells -Stimulation of bicarbonate secretion by epithelial cells -Stimulation of phospholipid secretion by epithelial cells -Enhancement of mucosal blood flow and oxygen delivery to epithelial cells via local vasodilation -Increased epithelial cell migration towards the luminal surface (restitution) -Enhanced epithelial cell proliferation  Primarily due to inhibition of COX-I	-Stimulation of clygoprotein (mucin) secretion by epithelial cells -Stimulation of bicarbonate secretion by epithelial cells -Stimulation of phospholipid secretion by epithelial cells -Enhancement of mucosal blood flow and oxygen delivery to epithelial cells via local vasodilation -Increased epithelial cell migration towards the luminal surface (restitution) -Enhanced epithelial cell proliferation  Primarily due to inhibition of COX-I	■ The nonsecretory cytoprotec	ctive effects of PG include:
-Stimulation of bicarbonate secretion by epithelial cells -Stimulation of phospholipid secretion by epithelial cells -Enhancement of mucosal blood flow and oxygen delivery to epithelial cells via local vasodilation -Increased epithelial cell migration towards the luminal surface (restitution) -Enhanced epithelial cell proliferation  Primarily due to inhibition of COX-I	- Stimulation of bicarbonate secretion by epithelial cells - Stimulation of phospholipid secretion by epithelial cells - Enhancement of mucosal blood flow and oxygen delivery to epithelial cells via local vasodilation - Increased epithelial cell migration towards the luminal surface (restitution) - Enhanced epithelial cell proliferation  Primarily due to inhibition of COX-I		
-Stimulation of phospholipid secretion by epithelial cells -Enhancement of mucosal blood flow and oxygen delivery to epithelial cells via local vasodilation -Increased epithelial cell migration towards the luminal surface (restitution) -Enhanced epithelial cell proliferation  Primarily due to inhibition of COX-I	- Stimulation of phospholipid secretion by epithelial cells - Enhancement of mucosal blood flow and oxygen delivery to epithelial cells via local vasodilation - Increased epithelial cell migration towards the luminal surface (restitution) - Enhanced epithelial cell proliferation  Primarily due to inhibition of COX-I		
-Enhancement of mucosal blood flow and oxygen delivery to epithelial cells via local vasodilation -Increased epithelial cell migration towards the luminal surface (restitution) -Enhanced epithelial cell proliferation  Primarily due to inhibition of COX-I	-Enhancement of mucosal blood flow and oxygen delivery to epithelial cells via local vasodilation -Increased epithelial cell migration towards the luminal surface (restitution) -Enhanced epithelial cell proliferation  Primarily due to inhibition of COX-I		
epithelial cells via local vasodilation  -Increased epithelial cell migration towards the luminal surface  (restitution)  -Enhanced epithelial cell proliferation  Primarily due to inhibition of COX-I	epithelial cells via local vasodilation  Increased epithelial cell migration towards the luminal surface  (restitution)  Enhanced epithelial cell proliferation  Primarily due to inhibition of COX-I		
-Increased epithelial cell migration towards the luminal surface (restitution) -Enhanced epithelial cell proliferation  Primarily due to inhibition of COX-I	-Increased epithelial cell migration towards the luminal surface (restitution) -Enhanced epithelial cell proliferation  Primarily due to inhibition of COX-I		
(restitution)  -Enhanced epithelial cell proliferation  Primarily due to inhibition of COX-I	(restitution)  -Enhanced epithelial cell proliferation  Primarily due to inhibition of COX-I	•	
-Enhanced epithelial cell proliferation of COX-I	-Enhanced epithelial cell proliferation of COX-I		ation towards the luminal surface
-Enhanced epithelial cell proliferation of COX-I	-Enhanced epithelial cell proliferation of COX-I	,	
UpToDate, 2017, "Pathogenesis of gastroduodenal toxicity"	PINWCEK, UpToDate, 2017, "Pathogenesis of gastroduodenal toxicity"	<ul><li>Enhanced epithelial cell prolif</li></ul>	
		UpToDate, 2017, "Pathogenesis of	f gastroduodenal toxicity"
		-Enhanced epithelial cell prolif	feration of COX-I

# NSAIDS and Gastrointestinal Toxicity (cont'd)

- Spectrum of gastroduodenal mucosal injury
  - Ranges from subtle alterations in gastric mucosal barrier function → microscopic damage to surface cells → gross injury visible through an endoscope or at the time of surgery for an ulcer complication
  - Aspirin-induced gastric injury is also associated with inhibition of vascular endothelial growth factor

Painweek, UpToDate, 2017, "Pathogenesis of gastroduodenal toxicity"

<b>NSAIDS and Gastrointestinal</b>	Toxicity	(cont'd)
------------------------------------	----------	----------

- Gastric damage
  - -GI mucosa uses COX-1 to generate mucosal-protective PGs
  - -Aspirin doses as low as 10 mg/day inhibit gastric PG generation considerably and can damage the stomach
  - -After stopping low-dose aspirin, human stomach requires 5-8 days to recover its COX-1 activity and synthesize protective PGs (very slow turnover of gastric COX-1)

	1	۱Λ	еκ
-	II N	νv	CN.

UpToDate, 2017, "Pathogenesis of gastroduodenal toxicity"

#### **NSAIDS and Gastrointestinal Toxicity (cont'd)**

- NSAID use and H. pylori infection are independent and synergistic risk factors for uncomplicated and bleeding PUD
  - -The risk of uncomplicated PUD is significantly higher among H. pylori positive compared with H. pylori negative NSAID users
  - -Ulcers were common in H. pylori positive compared with H. pylori negative patients irrespective of NSAID use and in NSAID users compared with nonusers irrespective of H. pylori status

PainWeek UpToDate, 2017, "Pathogenesis of gastroduodenal toxicity"

# **Risk of Gastrointestinal Complications**

- COX-2 inhibitors are associated with a reduced risk of GI bleeding compared to nonselective NSAIDs
  - -Relative risk 0.6 (95% CI 0.4-0.9)
  - -But greater risk as compared to placebo
- Any potential GI sparing effect with selective COX-2 inhibitors is eliminated when taken concurrently with low-dose aspirin therapy for prevention of CV disease

PainWeek. UpToDate, 2017, "Primary prevention of gastroduodenal toxicity"

NC	ΔIDe	and	Cardio	vaecu	lar D	icasca

- NSAIDs have been associated with increased risk of:
  - -Myocardial infarction
  - -Stroke
  - -Heart failure
  - -Atrial fibrillation
  - -Cardiovascular death

Risk in patients without known CV disease:

I-2 excess events or less per 1000 person-years

Painweek.

# Risk of Acute MI in "The Real World"

- Objective to characterize the determinants, time course, and risks of acute MI associated with use of NSAIDs
- Design systematic review followed by a one stage Bayesian individual patient data meta-analysis
- Systematic Review studies in general or geriatric population, documented acute MI as specific outcome, studied traditional and selective NSAIDs, allowed for timedependent analysis, and minimized effects of confounding and misclassification bias

PainWeek, Bally M et al. BMJ 2017;357:j1909 | doi: 10.1136/bmj.j1909

# Risk of Acute MI in "The Real World" (cont'd)

- Cohort of 446,763 individuals, with 61,460 AMIs
- Taking any dose of NSAID for 1 week, 1 month or > 1 month was associated with increased risk of AMI

NSAID	Odds Ratio (95% CI)
Celecoxib	1.24 (0.91-1.82)
Ibuprofen	1.48 (1.00-2.26)
Diclofenac	1.50 (1.06-2.04)
Naproxen	1.53 (1.07-2.33)
Pofocovih	1 59 (1 07 2 17)

**PaiN**WEEK. Bally M et al. BMJ 2017;357:j1909 | doi: 10.1136/bmj.j1909

#### Risk of Acute MI in "The Real World" (cont'd)

- Using a Bayesian meta-analysis of individual patient data and studying real world settings, it is shown that all traditional NSAIDs, including naproxen, appear to be associated with an increased risk of AMI
- The risk with celecoxib does not seem to be greater than that with traditional NSAIDs. Onset of risk occurs in the first week
- Short term use for 8-30 days at a high daily dose (celecoxib > 200 mg, diclofenac > 100 mg, ibuprofen > 1200 mg, and naproxen > 750 mg) is associated with the greatest harms, without obvious further increases in risk beyond the first 30 days

9	2	7	۱۸		Ω	V
		₽.	IV V	$\sim$	$\cdot$	1>

Bally M et al. BMJ 2017;357:j1909 | doi: 10.1136/bmj.j1909

#### So you have heart disease and your knees hurt...

- PRECISION trial compared cardiovascular safety of celecoxib, ibuprofen, and naproxen
- •24,081 patients with osteoarthritis (90%) or rheumatoid arthritis (10%) and established CV disease or increased risk of developing CV disease were randomized to receive:
  - Celecoxib 100 mg twice daily
  - -Ibuprofen 600 mg three times daily
- -Naproxen 375 mg twice daily
- Mean treatment duration was 20.3 months, and the mean follow-up period was 34.1 months
- About half were taking low-dose ASA at baseline

PaiNWEEK, SE Nissen et al. NEJM 2016 Nov 13 (epub)


#### So you have heart disease and your knees hurt...


- Primary outcome event (CV death (including hemorrhagic death), nonfatal MI or nonfatal CVA)
- 68.8% patients DC'ed study drug; 27.4% DC'ed during follow up


Celecoxib		Ibuprofen		Napı	oxen
Intent to treat	On treatment	Intent to treat	On treatment	Intent to treat	On treatment
188 (2.3%)	134 (1.7%)	201 (2.5%)	155 (1.9%)	218 (2.7%)	44 (1.8%)

- Risk of GI events significantly lower with celecoxib than naproxen or ibuprofen
- Risk of renal events significantly lower with celecoxib than ibuprofen, but celecoxib not significantly less than naproxen

PaiNWeek. SE Nissen et al. NEJM 2016 Nov 13 (epub)







Limitations	
Dosage of celecoxib was limited to 200 mg per day, lower than doses previously associated with CV toxicity     Ibuprofen and naproxen doses were allowed to be increased	
- Ibuprofen and naproxen (but not celecoxib) inhibit aspirin binding to	
platelet COX-1, thus the cardioprotective effects of aspirin may have been blunted in patients who were taking ibuprofen or naproxen	
■ Conclusion  — Researchers state celecoxib is noninferior to ibuprofen and naproxen	
from a cardiovascular perspective	
- Others state the celecoxib dose is too low to support this conclusion	
SE Nissen et al. NEJM 2016 Nov 13 (epub)	
Wait a second	

- "The Risk of Major NSAID Toxicity with Celecoxib, Ibuprofen or Naproxen: A Secondary Analysis of the PRECISION Randomized Controlled Clinical Trial."
  - -Daniel H. Solomon, M. Elaine Husni, Peter A. Libby, Neville D. Yeomans, AM Lincoff, Thomas F. Luscher, Venu Menon, Danielle M. Brennan, Lisa M. Wisniewski, Steven E. Nissen, Jeffrey S. Borer.
  - -Accepted manuscript: The American Journal of Medicine (2017), http://dx.doi.org/doi:10.1016/j.amjmed.2017.06.028

R	esi	ılts

- During follow-up, major toxicity sustained:
   Celecoxib 4.1% subjects
   Naproxen 4.8% subjects

  - Ibuprofen 5.3% subjects
- This translated into numbers needed to harm of:
  - 135 for naproxen compared with celecoxib
- 82 for ibuprofen compared with celecoxib
   Among patients with symptomatic arthritis who had moderate to high risk of CV events, about 1 in 20 had a major toxicity over 1-2 years
   Patients using naproxen or ibuprofen experienced significantly higher risk of major toxicity than those using celecoxib

Painweek.

Solomon DH et al. Am J Med, http://dx.doi.org/doi:10.1016/i.amimed.2017.06.028

NSAIDs	ALL AND ALL DESIGNATION OF THE SECOND
<b>Pain</b> week.	

Da.	iN	\۸	$\bigcirc$	<b>&lt;</b>
		V V	<u> </u>	\ ⊚

**Medical Cannabis** 

# So who's with me?

I would prescribe or recommend cannabis (medical marijuana) for a patient with a disease or symptom where cannabis has been shown to be helpful.

- A. Absolutely, where do I sign?
- B. Maybe, I need more convincing
- C. Not in this lifetime

# Let's get that prescription pad out...

- Survey of 520 members of the Colorado Academy of Family Physicians (2013)
  - 19% believed physicians should recommend medical cannabis
  - -80% agreed it should be incorporated into medical school education
  - -82% agreed that it should be included in residency training
  - -92% agreed it should be a topic of CME for practicing MDs
  - Majority agreed that there are significant mental and physical health risks associated with marijuana

PainWeek, Kondrad E, at al. Colorado family physicians' attitudes toward medical marijuana. J Am Board Fam Med 2013;26:52-60.

# **Current State of Affairs** Medical marijuana laws Legal in 29 US states, the District of Columbia, Guam, and Puerto Rico

#### **Cannabis**

- "Cannabis" is the genus name for the entire plant
- 3 generally accepted varieties: Cannabis sativa, Cannabis indica, and Cannabis ruderalis
- Can be given orally, sublingually, rectally, topically, or inhaled
- Crude product contains > 460 active chemicals and > 100 cannabinoids δ-9-tetrahydrocannabinol (THC)
  - Cannabidiol (CBD)



PainWeek, National Highway Traffic Safety, Administration. Cannabis/Marijuana (4-4-denthydrocannabina), THC1, http://www.nintsa.gov/jeografic/sipy/dis-Sonity, GL. Medical cannabis: basic content & clinical applications: what clinicates event to both and why Eventy Farms, MA: COM Press, 2015.

#### **Clinical Effects of Cannabis Symptom Relief Disease Management** Arthritis Addiction •ADHD, PTSD Anxiety, tension, stress Cancer treatments Depression Gastrointestinal disorders ■ Digestive problems ■HIV/AIDS Inflammation Insomnia ■ Nausea and vomiting Migraine ■Pain ■ Movement disorders Spasms and convulsions ■ Multiple sclerosis

PainWeek, Smith, G.L. Medical cannable: basic science & clinical applications: what clinicians need to know and why. Beverly Farms, MA: OEM P

Cannabinoids for Medical Use
A Systematic Review and Meta-analysis

Penny F. Whiting, PhD; Robert F. Wolff, MD; Sohan Deshpande, MSc; Marcello Di Nisio, PhD; Steven Duffy, PgD Adrian V. Hernandez, MD, PhD; J. Christian Keurentjes, MD, PhD; Shona Lang, PhD; Kate Misso, MSc; Steve Buder MSc-Simone Schmidliofer MSc-Marie Mextuood BhD. Jos Klelinen MD, BhD

Painweek

#### 

# Systematic Review (cont'd)

Indication Cannabinoids		Therapeutic Outcome
Spasticity due to MS or paraplegia	Nabiximols, dronabinol, nabilone, THC/CBD, smoked THC	Cannabis improved spasticity but failed to reach SS. More patients had global improvement
Anxiety disorder	Cannabidiol vs placebo	Greater improvement in anxiety on visual analogue mood scale (SS)
Sleep disorder	Nabilone	Greater effect than placebo (SS)
Psychosis	Cannabidiol vs placebo	No difference in outcomes
Glaucoma	THC, cannabidiol, cannabidiol oromucosal spray	No difference when compared to placebo

PainWeek. Whiting PF, et al. Cannabinoids for medical use: a systematic review and meta-analysis. JAMA 2015;313(24):2456-2473

#### ■ Chronic pain

- Cross-sectional retrospective survey of 244 medical cannabis patients with chronic pain in Michigan
  - Medical cannabis use associated with 64% decrease in opioid use, decreased number and side effects of medications, and improved quality of life (45%)

#### ■ Neuropathic pain

- Randomized, double-blind, placebo-controlled, crossover study of
- 16 patients with treatment-refractory painful diabetic neuropathy
  - Vaporized cannabis associated with a dose-dependent effect on spontaneous pain, with the high dose showing the strongest effect size

Path Week IS, Libras E, Clauw DI. Medical cannabis use in associated with decreased opiate medication use in a retrospective cross-sectional survey of patients with

# **Muscle Spasticity**

- Commonly associated with painful spasms and sleep disturbances, and contributes to increased morbidity
- Largely studied in patients with multiple sclerosis
- Systematic review (Koppel et al.)
  - Nabiximols (THC:CBD extract) and orally administered THC are "probably effective" for reducing patient-reported spasticity scores
  - Oral cannabis extract is "established as effective" for reducing patient-reported spasticity scores

PainWeek Koppel BS, Brust, XC, Fife T, et al. Systematic review: Efficacy and safety of medical marijuana in selected neurologic disorders: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2014;82(17):1556-1563.


# **Nausea and Vomiting**

- Nabilone and dronabinol approved in 1985 for nausea and vomiting associated with cancer chemotherapy (CINV)
- No evidence to support use of cannabinoids over current firstline antiemetic therapies
- No good-quality randomized trials investigating plant based cannabis, either inhaled or ingested orally, but abundance of anecdotal reports
- Consider as adjunctive therapy in refractory cases of CINV

Painweek.

# **Safety of Cannabis**

- Adverse effects
- Cardiovascular concerns
- Other long-term consequences
- Risk of addiction and dependence
- Contraindications/precautions



Painweek.

# **Common Adverse Effects**

- Nausea
- Fatigue/weakness
- Dry mouth
- Cough
- Dizziness or vasovagal symptoms
- Tachycardia
- Feelings of intoxication, disorientation, confusion
- Hallucinations, behavioral or mood changes
- Psychosis, euphoria/dysphoria, anxiety



PainWeek. Koppel BS, et al. Systematic review: efficacy an Neurology 2016; 82(17): 1555-63

- Characterized by chronic cannabis use, cyclic episodes of nausea and vomiting, and the learned behavior of hot bathing
- Typically seen in young adults with a long history of cannabis use
  - -One study found an average duration of cannabis use prior to onset of recurrent vomiting =  $6.3 \pm 3.4$  years

Painweek
----------

Galli JA, Sawaya RA, Friedenberg FK. Curr Drug Abuse Rev. 2011;4(4):241-9.

#### Cannabinoid Hyperemesis Syndrome (cont'd)

- - Pre-emetic or prodromal

  - Cran last for months or years
     Patients develop early morning nausea, a fear of vomitting, and abdominal discomfort
     Hyperemetic
     Paroxysms of intense and persistent nausea and vomitting, commonly described as overwhelming and incapacitating
     Patients take numerous hot showers throughout the day to alleviate symptoms (learned behavior); rapidly becomes a compulsive behavior

  - Recovery
     Can last for days, weeks, or months
  - Relative wellness and normal eating patterns
     Weight is regained and bathing returns to regular frequency

PaiNWeek, Galli JA, Sawaya RA, Friedenberg FK. Curr Drug Abuse Rev. 2011;4(4):241-9.

# Don't go breaking my heart...



- Nationwide inpatient sample of patients age 18-55 years old discharged from hospitals in 2009 & 2010
  - Compared cardiovascular disease rates in patients reporting marijuana use vs nonreporters
  - After adjusting for confounders, marijuana use was independently associated with a 26% increase in the risk of stroke, and a 10% increase in the risk of developing heart failure
- Limited evidence of a statistical association between cannabis use and the triggering of acute MI

PainWeek, https://www.acc.org/about-acc/press-releases/2017/03/09/14/05/marijuana-use-associated-with-increased-risk-of-stroke-heart-failure

Long-Term (	Use of	Cannab	į
Cognitive dysfunc		-41	_

vith worse verbal recall in middle age but doesn't appear to affect other domains of cognitive function. More evidence with earlier onset of use

#### Pulmonary damage

- Conflicting data; many studies confounded by cigarette smoking

  Occasional & low cumulative marijuana use was not associated with adverse effects on pulmonary function (≤ 7 joint-years of life exposure)
- Chronic low-level use over 20 years associated with an increase in FEV1; diminishes and may reverse in high-level users
  - Chronic use associated with bronchitis and airway infections

#### Periodontal disease

- Periodontal disease found in 55.6% of people with > 15 joint-years of marijuana use compared with only 13.5% who never used cannabis

Painweek	ı
----------	---

#### Psychosis and schizophrenia

- Is-year follow-up of >50,000 Swedish males found that those who tried cannabis by age 15 were 2.4 times more likely to be diagnosed with schizophrenia than those who had not Meta-analysis reported a pooled odds ratio of 1.4 (95% CI: 1.20, 1.65) of psychotic symptoms or psychotic disorder among those who had ever used cannabis; OR = 2.09 (95% CI: 1.54, 2.84) in regular users The risk of developing psychosis doubles from ~7 in 1000 nonusers to 14 in 1000 for regular cannabis users; important for patients with an affected first-degree relative **intertive disorders**

#### Affective disorders

- No longitudinal association between cannabis use and incidence of depression/anxiety has been documented
- Cannabis use associated with increased symptoms of mania and hypomania in individuals with bipolar disorders

٠.	1	۱۸.	(	/

Auer R, et al. AMA intere Med 2015;176(3):352-361; Plescher MJ, et al. AMA intere Med 2015;276(3):352-361; HII KP, et al. AMA 2015;215(21):2328-2329.


Danielson AK, et al. Austral of Affective Discotors 2015;181:202-106. Audits son S, Engitters A, Allebeck P, et al. Canada and infloophrens. A bagistation tody of Swedin

# Long-Term Use of Cannabis (cont'd)

#### Cancer

- -Cannabis contains at least 33 carcinogens and may be contaminated with pesticides
- -Research is conflicting
  - Some studies have suggested associations with cancers of the brain, testes, prostate, cervix, and rare pediatric cancers
  - · Conflicting data re: associations with head and neck squamous cell carcinoma, bladder cancer, and non-Hodgkin's lymphoma
  - Cannabidiol (CBD) may have an antineoplastic effect?

	01
inwe	
	ヒト



# **Contraindications/Precautions**

- Cannabis allergy
- Bipolar disorder
- Patients suffering from or at risk of developing schizophrenia
- Substance abuse (past or current)
- Pregnant and/or breastfeeding women
- Coronary heart disease

FRINGER, Smith, GL. Medical cannabic: basic science & clinical applications: what clinicians need to know and why. Beverly Farms, MA: OEM Press, 20 Subman C, Kingdey K. Medical Cannabic Printer for Healthcare Professionals. Minneson Medical Subston, 2014.

# Our Responsibility as, Healthcare Providers

- Be familiar with state rules and regulations regarding medical cannabis
- Present a balanced perspective, identifying both the potential health benefits and risks associated with medical cannabis use if patients inquire
- Frequently **reassess** our patients using medical cannabis for both efficacy and toxicity

<b>Pain</b> V/C	eK.
-----------------	-----

# **Opioid Prescribing**

A review of the CDC Guidelines for Chronic Pain in the United States—2016

#### **Sound Familiar?**

■ Mr. M is a 40 yo AA male who presents with chronic pain after having many surgeries since a car accident in 2007. He reports uncontrolled pain on his current analgesics — including acetaminophen, ibuprofen, and cyclobenzaprine. He reports being unable to work due to this severe pain and that his current regimen is just not working. He found the only time he was able to work was when he was on Oxycontin 10 mg twice daily. This was stopped when he went back to work, however, and he has since left work on disability.

Painweek.

#### **Sound Familiar?**

• Mr. M is a 50 yo AA male admitted to the hospital with stage 4 lung cancer. He reports severe pain in his femur due to a boney metastasis. He reports being unable to walk around and finds working with physical therapy to be impossible. His current analgesic regimen includes acetaminophen, ibuprofen, and cyclobenzaprine but it is not enough. He tells you that his friend got good relief with Oxycontin when he had cancer. He is on disability from work and the current plan is to start chemotherapy and radiation.

T	he	Due

Chronic Pain

- ■25 to 39 million people experience daily chronic pain; \$560-\$630 billion annually
- 10 million people are disabled due to
- 40%-70% of patients with chronic pain are not receiving proper medical treatment

Opioid Misuse/Abuse/Addiction

- ■80% of all opioid prescriptions are written in the US
- ■16,000 to 19,000 overdose deaths annually; \$20 to \$120 billion in related expenses
- ■53% of people age 12 or older abusing analgesics report getting them from a friend or relative

Painweek.

#### NIH Role of Opioids in the Treatment of **Chronic Pain 2014**

- Patients, providers, and advocates all agree:
  - -There is a subset of patients for whom opioids are an effective treatment method for their chronic pain
  - -Limiting or denying access to opioids for these patients can be harmful
  - Patients can be safely monitored using a structured approach, which includes optimization of opioid therapy, management of adverse effects, and brief follow-up visits at regular intervals
  - Recommendations regarding the clinical use of opioids should avoid disruptive and potentially harmful changes in patients currently benefiting from this treatment

Painweek.

# NIH Role of Opioids in the Treatment of Chronic Pain 2014 (cont'd)

- The approach should be individualized, based on a comprehensive clinical assessment that is conducted with dignity and respect and without value judgments or stigmatization of the patient
- This initial evaluation would include an appraisal of:
- Pain intensity, functional status, and quality of life
   Known risk factors (history of or current substance use disorders; mood, stress, or anxiety disorders; medical comorbidity; and potential drug-drug interactions).
- Potential to redesign the electronic health record to facilitate such an assessment
- Incorporate the use of other clinical tools (eg, PDMPs) into this assessment
- Triage those screening at highest risk for harm to more structured and higher intensity monitoring approaches

NIH Role of Opioids	s in the Treatment of
Chronic Pain 2014	(cont'd)

- Looked at same data as CDC guideline and found:
   Insufficient data to guide appropriate patient assessment, opioid selection, dosing strategies, or risk mitigation.
   Need for high-quality research that focuses on establishing the appropriateness of long-term opioid freatment for the management of chronic pain.
- Recommendations
- 1. Sponsor research, development, and quality improvement initiatives
- In the absence of definitive evidence, clinicians and health care systems should follow current guidelines by professional societies about which patients and which types of pain should be treated with opioids, and about how best to monitor patients and mitigate risk for harm
- NIH or other federal agencies should sponsor conferences to promote harmonization of guidelines of professional organizations

#### CDC Guidelines 2016

- Intention

  For primary care providers who are treating patients with chronic pain (lasting > 3 months or past time of normal tissue healing) in outpatient settings

  For patients 18 years of age or older with chronic pain outside of active cancer treatments, palliative care, and end of life

  To improve communication about benefits and risks of opioids for chronic pain, improve safety and effectiveness of pain treatment, and reduce risks with long-term onioid therapy
- Inightee safey and enecetiveness of pain leadinglift, and reduce tisks will long-term opioid therapy
   Clinical decision-making should be based on clinician-patient relationship and an overall understanding of the patient's functional status, clinical situation, and life context
   Recommendations, not prescriptive standards
- Clinicians should consider the circumstances and unique needs of each patient when providing care

Painweek.

#### **Evidence Review**

- Efficacy of short-term opioids has been established (RCT <12 weeks duration)
  - High percentage of patient discontinued long-term use due to lack of efficacy and intolerable adverse effects
  - Difficult to extrapolate this data to long-term use
- Categories of key questions for clinical evidence review
  - Effectiveness and comparative effectiveness
  - -Harms and adverse events
  - Dosing strategies
  - -Risk assessment and risk mitigation strategies
  - Effect of opioid therapy for acute pain and long-term use

<b>Evidence</b>	Paviaw I	(cont'd)
Evidence	Review (	(cont a)

- Evidence for long-term use
  - -Limited data outside of end of life care
  - No study looked at utilization > 1 year for chronic pain
     Most placebo-controlled RCTs were 6 weeks or less in duration
  - Suggestive of dose-dependent effects on risks of opioid use
     Including opioid-use disorder, overdose, and death
  - All evidence is either type 3 or type 4
  - Risk of misuse associated with history of substance use disorder, younger age, major depression, and use of psychotropic medications
     Other risks: CV events, endocrinologic harms, road trauma
- Developed 12 recommendations

#### Nonpharmacologic and Nonopioid Therapy

- Nonpharmacologic therapy (exercise, CBT) to reduce pain and improve function
- Nonopioids (NSAIDs, anticonvulsants, antidepressants, acetaminophen) should be used when benefits outweigh risks
- Nonpharmacologic and nonopioids should be used in combination
- Opioids should not be considered first-line or routine for chronic pain
- Long-term benefits of nonopioid therapies is also limited but risks in the short-term are also much lower
- If opioids are used, they should be combined with nonpharmacologic and nonopioid therapy

Painweek.

# Nonpharmacologic and Nonopioid Therapy

- Many systematic reviews in various pain syndromes
- Variable evidence supporting gabapentin, pregabalin, and duloxetine in diabetic peripheral neuropathy and fibromyalgia; TCAs and antidepressants in postherpetic neuralgia; NSAIDs for low back pain (LBP)
- Evidence supporting exercise in fibromyalgia, osteoarthritis, LBP
- Cognitive behavioral therapy seems to have positive lasting effects on mood, not as much on pain
- Improved data on many nonpharmacologic interventions is needed

u = 0		
Key Findings 24% of controls had dosages >50 MME/d; 59% had doses above this level		
20- <50 MME/d, 50- <100 MME/d, ≥100 MME/d associated with HR 1.88;4.63;7.18 vs. 1- <20 mg MMEE/d  Steady increase in dose-dependent manner; rate of increased decreased after 200 mg MME/d; concurrent		
benzo given in 61% of deaths		
20- <50 MME/d, 50- <100 MME/d, ≥100 MME/d associated with HR 1.4, 3.7, 8.9 vs. 1- <20 mg MMEE/d	-	
20- <50 MME/d, 50- <100 MME/d, 100-199 MME/d associated with OR 1.3,1.9,2.0 vs. I- <20 mg MMEE/d		
>100 MME, ≥4 prescribers, ≥4 pharmacies (adjusted OR 11.2, 6.5, 6.0) - at least one factor present in 55% of deaths		
Among patients on 50-100 MME/d, overdose risk greatest with >1830 MME cumulatively over 6 months		
>40 MME has 12.2 greater odds of overdose vs. lower or no opioid prescription		
20- <50 MME/d, 50- <100 MME/d, ≥100 MME/d associated with OR 1.5, 2.2, 4.1 vs. 1- <20 mg MME/d		
week.		
	1	
Abrupt Cut-off or Gradual Shift?		
Abrupt Cut-off or Gradual Shift?  Prospective observational cohort with 1 year follow-up In NC using PDMP with name-linked mortality data – 2,182,374 opioid analgesic patients		
Prospective observational cohort with 1 year follow-up In NC using PDMP with name-linked mortality data – 2,182,374 opioid analgesic patients Outcome: overdose deaths involving opioids in a primary or additive role		
Prospective observational cohort with 1 year follow-up In NC using PDMP with name-linked mortality data – 2,182,374 opioid analgesic patients Outcome: overdose deaths involving opioids in a primary or additive		
Prospective observational cohort with 1 year follow-up In NC using PDMP with name-linked mortality data – 2,182,374 opioid analgesic patients Outcome: overdose deaths involving opioids in a primary or additive role 22.8% of residents were prescribed opioids, 629 overdose deaths –		
Prospective observational cohort with 1 year follow-up In NC using PDMP with name-linked mortality data – 2,182,374 opioid analgesic patients Outcome: overdose deaths involving opioids in a primary or additive role 22.8% of residents were prescribed opioids, 629 overdose deaths – 50% had active opioid Rx at time of death Mortality rates increased gradually across a range of average daily		

# **Determining When to Initiate or Continue Opioids for Chronic Pain**

- Nonpharmacologic therapy and nonopioid pharmacologic therapy are preferred ...opioid therapy only if expected benefits for both pain and function are anticipated to outweigh risks... If opioids are used...combined with nonpharmacologic therapy and nonopioid pharmacologic therapy, as appropriate
   Before starting ...establish treatment goals ...realistic goals for pain and function...consider how therapy will be discontinued if benefits do not outweigh risks ...Continue opioid therapy only if...clinically meaningful improvement in pain and function that outweighs risks to patient safety
   Before starting and periodically...discuss with patients known risks and realistic benefits ...and patient and clinician responsibilities...

Opioid	Selection	n, Dosage	, Duration
Follow-	up, and	Discontinu	uation

- ...**Prescribe immediate-release opioids** instead of extended-release/long-acting (ER/LA) opioids
- iong-acting (EFIZA) opioios
  ...Prescribe the lowest effective dosage. ...use caution...at any
  dosage...carefully reassess ...benefits and risks when increasing
  dosage to ≥50 MME...avoid increasing dosage to ≥90 MME or
  carefully justify a decision to titrate dosage to ≥90 MME per day
- are retuinly justing a decision to titrate dosage to be which per day
  ...For acute pain, ...prescribe the lowest effective dose of immediaterelease opioids and...no greater quantity than needed for the
  expected duration of pain... 3 days or less will often be sufficient; >7
  days will rarely be needed
  ...Evaluate benefits and harms...within 1-4 weeks of starting... or of
  dose escalation...and of continued therapy...every 3 months or
  more frequently. If benefits do not outweigh harms ...optimize
  therapies and ...taper opioids to lower dosages or to D/C opioids

## Assessing Risk and Addressing Harms of **Opioid Use**

- 8. Before starting and periodically during continuation ...evaluate risk factors for opioid-related harms...incorporate...strategies to mitigate risk, including considering offering naloxone when factors that increase risk for opioid overdose...are present
- opioid voerdoe-mate preserription drug monitoring program (PDMP)
  data...when starting opioid therapy for chronic pain and periodically during
  opioid therapy for chronic pain, ...every prescription to every 3 months.
- 10. ...Use urine drug testing before starting opioid therapy and...at least annually ... (category B, Type 4)
  11. Avoid prescribing opioid pain medication and benzodiazepines concurrently ....
- 12. ...Offer or arrange evidence-based treatment...for patients with opioid use disorder

Painweek.

#### What providers are saying The Word on the Street

- AMA is largely supportive, but concerned about the evidence base informing some of the
  recommendations; conflicts with existing state laws and product labeling; and
  possible unintended consequences, includes access and insurance coverage
  limitations for non-pharmacologic treatments, especially comprehensive care; and the
  potential effects of strict dosage and duration limits on patient care.
   Pattec N. trans, W.D. he AMS based Caller et al. AMS and the top to the Decorption Abuse
- [T]here are few well-controlled clinical studies on opioid-prescribing methods for chronic pain—appropriate access to opioids could be negatively affected by federal guidelines based on admittedly weak data. It is important to note that the CDC guidelines are in this respect, an iteration of well-accepted medical principles of drug prescribing: to use the lowest effective dose for the shortest possible duration.

PRINWECK. https://wire.ama-assn.org/delivering-care/what-physicians-are-saying-about-new-odc-opioid-guide

23

v	vr	12t	patie	nte	ara	621	/ın	n
v	V I	ıaı	pauc	III	aıc	3aı	/ I I I'	ч

- In 1 survey, 95% of pain patients said that the CDC guideline discriminated against them, and 93% said that if published as is, the guideline would be harmful to pain patients
- the guideline would be harmful to pain patients

  I would caution the CDC that putting these dosage limits in here would cause problems for patients...These recommendations have severe ramifications
- I have been on and off opiates for a few years. I do not have cravings for opiates. I am not addicted to opiates. I do think there has been a demonization of opiates among the medical community, as well as the CDC possibly and definitely the DEA, how do you decide which patients to continue, that really get benefits from this, and how do you decide which patients take them to get high?

.)-	ΝV	VEEK

https://www.painnewsnetwork.org/stories/2015/9/16/cdc-opioids-not-preferred-treatment-for-chronic-pair

#### What about this scenario?

• Mr. M is a 40 yo AA male who presents with chronic pain after having been treated for stage 2 lung cancer. He reports controlled pain on his current analgesics – including acetaminophen, ibuprofen, cyclobenzaprine, and oxycodone ER 30 mg PO Q12H and oxycodone IR 10 mg PO q6h PRN. His oncologist has deemed him to be in remission after lobectomy and chemo/radiation. He would like to continue on his current medications as his pain is tolerable, but his oncologist will no longer prescribe them for him since he will need frequent follow-up and monitoring and he will not need to be seen that often for his cancer follow-ups. He is still on disability posttreatment, but hopes to come off and get back to work soon

_	_	 
ויי∠ו		

#### A Need for Remediation?

- We need education and ongoing development and programming
- More studies are needed to determine dose limits, if they are indicated or beneficial
- Better support for those at risk or with addiction issues
- Need more patient-focused and individualized care
- Pain assessment and pain contracts!

_			~	<b>.</b>
	IN	W		
4.				



# 3's Company: COX-2 Inhibitors, Medicinal Marijuana, and Opioid Prescribing

Alexandra L. McPherson, PharmD, MPH
Palliative Care Clinical Pharmacy Specialist
MedStar Washington Hospital Center, Washington DC
alexandra.l.mcpherson@medstar.net

	_